ABSTRACT:
A new simple, accurate, precise and selective stability- indicating high performance liquid chromatographic (HPLC) method has been developed and validated for simultaneous estimation of Atazanavir and Ritonavir in tablet dosage form. An isocratic, reverse phase HPLC method was developed on Jasco HPLC system equipped with Grace C18 column (150 x 4.6 mm i.d.) using 10 mM Potassium dihydrogen phosphate buffer: Acetonitrile: Methanol (40: 40: 20, v/ v/v) as mobile phase and detection was carried out at 240 nm. Results were linear in the range of 50-500 µg mL-1 for Atazanavir and 25-400 µg mL-1 for Ritonavir. The retention time for Atazanavir and Ritonavir were 5.54 ± 0.02 and 6.82 ± 0.07 min. respectively. The drugs were subjected to stress condition of hydrolysis (acid, base), oxidation, photolysis and thermal degradation.
Cite this article:
Padmanabh B. Deshpande, Santosh R. Butle. Development and Validation of Stability-Indicating RP-HPLC Method for Determination of Atazanavir and Ritonavir. Research J. Pharm. and Tech. 7(11): Nov. 2014 Page 1231-1236.
Cite(Electronic):
Padmanabh B. Deshpande, Santosh R. Butle. Development and Validation of Stability-Indicating RP-HPLC Method for Determination of Atazanavir and Ritonavir. Research J. Pharm. and Tech. 7(11): Nov. 2014 Page 1231-1236. Available on: https://rjptonline.org/AbstractView.aspx?PID=2014-7-11-21